Zepbound vs Wegovy: Compare Differences & Prices

When choosing between Zepbound and Wegovy for weight loss, understanding the similarities and differences in their side effects can help you and your healthcare provider decide which medication might be the better fit for your individual needs. Both medications work by acting on hormones in the gut that influence hunger and fullness, and because of this, their side effects tend to overlap. However, there are some differences in how people tolerate these drugs, and knowing what to expect can help you manage any unwanted symptoms.

Both Zepbound and Wegovy are given as once-weekly injections under the skin. The most common side effects associated with both medications include gastrointestinal symptoms. Many users report nausea, constipation, diarrhea, and vomiting, especially when first starting the treatment or after a dose increase. These effects are usually mild to moderate and often improve over time as your body gets used to the medication. To help reduce these symptoms, both medications are started at a lower dose and increased gradually over the course of several weeks.

Here is a summary of the typical side effects you might experience:

• Nausea: This is the most frequently reported side effect for both Zepbound and Wegovy, with many people experiencing it during the first few weeks.

• Constipation and Diarrhea: Changes in bowel movements are common and can include both constipation and, less often, diarrhea.

• Vomiting: Although less common than nausea, some individuals may experience vomiting, which also tends to lessen over time.

• Stomach pain and indigestion: Some users notice discomfort or a feeling of fullness after eating small amounts.

There are also some differences in how these side effects can impact people. In recent clinical studies, the overall rate of people stopping their medication because of side effects was slightly lower for Zepbound than for Wegovy (about 6% for Zepbound and 8% for Wegovy). This means that most people on either medication are able to manage the side effects with the help of their healthcare team and continued use. One possible reason for this could be how Zepbound, which mimics two gut hormones instead of one, interacts with the body. However, individual experiences can vary, so monitoring how you feel and staying in touch with your healthcare provider is key.

Though rare, there are serious side effects to be aware of. Both medications can increase the risk of certain health conditions, such as pancreatitis (inflammation of the pancreas), gallbladder disease, and low blood sugar, especially if you are taking medications for diabetes alongside weight loss injections. Signs of these complications can include severe stomach pain, yellowing of the skin or eyes, or confusion. If you experience any of these symptoms, seek medical attention promptly.

Another important consideration is the specific conditions each medication is approved to treat, which may influence side effect monitoring. Wegovy is approved for adults and adolescents 12 years and older, making it an option for younger patients with certain health needs. Zepbound is approved only for adults, and it has additional proven benefits for people with obstructive sleep apnea, which may influence the choice of medication in those with this condition.

In summary, while Zepbound and Wegovy share many common side effects, most are manageable and tend to improve with time. Both have a similar safety profile when it comes to the most frequently reported symptoms, but a slightly lower discontinuation rate due to side effects has been observed with Zepbound in clinical studies. You should discuss your medical history, other medications, and any concerns with your healthcare provider to ensure the safest and most effective use of either medication for your weight management journey.

When choosing between Zepbound and Wegovy for weight management, it's important to understand which conditions each medication treats and the groups of people they are approved for. Both Zepbound (tirzepatide) and Wegovy (semaglutide) are prescription, once-weekly injection therapies designed to help people lose weight by working on appetite, hunger, and feelings of fullness. However, they differ in some of their specific uses and the populations they serve.

Zepbound is approved for use in adults with obesity or those who are overweight and have at least one weight-related medical problem, such as high blood pressure, high cholesterol, or obstructive sleep apnea. Specifically, Zepbound is also the first medication of its kind to be approved by the FDA for managing moderate-to-severe obstructive sleep apnea in people who are overweight or obese. This makes Zepbound a better option for adults who not only need help with weight loss but also struggle with sleep apnea, as clinical studies have found that it can lower the severity of this condition—and in some cases, help resolve it altogether. Zepbound works by acting like two hormones in the body (GLP-1 and GIP), which together can reduce appetite, improve feelings of fullness, and help lower blood sugar, making it effective for weight loss and related metabolic conditions.

Wegovy, on the other hand, is approved for both adults and adolescents aged 12 years and older. For adolescents, eligibility for Wegovy requires having a body mass index at or above the 95th percentile for their age and sex, which means meeting the medical definition of obesity—this is not just for those who are overweight, but for those who meet criteria for adolescent obesity. In adults and adolescents, Wegovy is mainly prescribed to help with chronic weight management for those with obesity or for those who are overweight and have at least one weight-related health problem.

A unique feature of Wegovy is its approval for people with certain chronic health conditions in addition to obesity. For example, Wegovy is the only GLP-1 medication currently approved to reduce the risk of serious heart problems—such as heart attack and stroke—in adults who have obesity or are overweight and also have a history of heart disease. This is a significant benefit for people with both weight and heart health concerns. Wegovy also has approval for treating a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) when there is moderate-to-severe scarring (fibrosis) present, offering a treatment option for those with this combination of liver disease and obesity.

To summarize the conditions treated and the populations served by each medication:

• Zepbound: Approved for adults with obesity or overweight and at least one weight-related health condition; uniquely approved for managing moderate-to-severe obstructive sleep apnea in this group.

• Wegovy: Approved for adults and for adolescents (12 years and older) with obesity (BMI at or above the 95th percentile for age/sex); for adults, also approved to reduce the risk of major heart problems in those with obesity or overweight and heart disease history; approved to treat MASH with liver fibrosis in adults.

Your healthcare provider will consider your overall health, age, the conditions you want treated, and your medical history when deciding which therapy may be right for you. For example, if you are an adult with significant sleep-related breathing problems, Zepbound may be preferred. Meanwhile, if you have heart concerns or are a teenager with obesity, Wegovy would likely be the recommended choice. Always discuss your medical conditions and treatment goals with your provider to determine which option best fits your needs.